Business Monitor International


Central America Pharmaceuticals & Healthcare Report

Published 06 February 2014

  • 67 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Central America Pharmaceuticals & Healthcare Report

BMI View: The Central American regional pharmaceutical and healthcare markets , consisting of the seven markets of Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama and Belize , will remain highly diverse . Panama and Costa Rica will outperform in compar ison with their regional peers , and improving healthcare investment should translate into higher consumption of medicines . However, the region's low per capita pharmaceutical spending and generic drugs' high market share has limited multinationals' growth potential in the region .

Headline Expenditure Projections

  • Pharmaceuticals: US$3.7bn in 2013 to US$3.8bn in 2014; +4.6%. Our forecast has been revised slightly downwards since Q114 due to less optimistic macroeconomic data.

  • Healthcare: US$17.1bn in 2013 to US$18.3bn in 2014; +7.2 %. Our forecast has been revised downwards since Q114 due to less optimistic macroeconomic data.

Risk/Reward Ratings: Based on our analysis and assessment of the market's appeal to pharmaceutical companies, in BMI's Q214 Pharmaceutical Risk/Reward Ratings (RRRs) the Americas scores 50.6 out of 100. This is below Western Europe (67), Central and Eastern Europe (52), and Asia Pacific (52), but above the Middle East and Africa (42) region. Of the seven Central American countries surveyed, at 45.2 Panama's RRR score ranks first, followed by Costa Rica (42.0), Belize (38.1), Guatemala (37.6), El Salvador (37.0), Honduras (32.6) and Nicaragua (32.3).

Key Trends And Developments

  • In January 2014, Bayer opened a new US$3mn pharmaceutical plant in Costa Rica to develop a novel product for permanent birth control. The plant will be located in the Metropolitan Free Zone in Aurora de Heredia and initially hire around 50 people. It will have the capacity to produce between 40,000 and 80,000 kits, according to Rafael Villarroel, president of Bayer Central America and the Caribbean.

  • In November 2013, Panama's International Center of Radiosurgery and Radiation...

Table of Contents

BMI Industry View
7
SWOT
9
SWOT
9
Industry Forecast
10
Pharmaceutical Market Forecast
10
Table: Central America Pharmaceutical Sales, Historic Data And Forecasts
11
Guatemala
11
Table: Guatemala Pharmaceutical Sales Forecasts
11
Costa Rica
12
Table: Costa Rica Pharmaceutical Sales Forecasts
12
El Salvador
12
Table: El Salvador Pharmaceutical Sales Forecasts
13
Honduras
13
Table: Honduras Pharmaceutical Sales Forecasts
13
Panama
14
Table: Panama Pharmaceutical Sales Forecasts
14
Nicaragua
14
Table: Nicaragua Pharmaceutical Sales Forecasts
15
Belize
15
Table: Belize Pharmaceutical Sales Forecasts
15
Healthcare Market Forecast
16
Table: Central America Healthcare Expenditure Trends, Historical Data and Forecasts
17
Guatemala
17
Table: Guatemala Healthcare Expenditure Forecasts
17
Costa Rica
18
Table: Costa Rica Healthcare Expenditure Forecasts
18
El Salvador
18
Table: El Salvador Healthcare Expenditure Forecasts
19
Panama
19
Table: Panama Healthcare Expenditure Forecasts
20
Honduras
20
Table: Honduras Healthcare Expenditure Forecasts
21
Nicaragua
21
Table: Nicaragua Healthcare Expenditure Forecasts
21
Belize
22
Table: Belize Healthcare Expenditure Forecasts
22
Pharmaceutical Trade Forecast
23
Guatemala
24
Table: Guatemala Pharmaceutical Trade Data And Forecasts (US$mn)
24
Costa Rica
25
Table: Costa Rica Pharmaceutical Trade Data And Forecasts (US$mn)
25
El Salvador
25
Table: El Salvador Pharmaceutical Trade Data And Forecasts (US$mn)
26
Panama
26
Table: Panama Pharmaceutical Trade Data And Forecasts (US$mn)
26
Honduras
26
Table: Honduras Pharmaceutical Trade Data And Forecasts (US$mn)
27
Nicaragua
27
Table: Nicaragua Pharmaceutical Trade Data And Forecasts (US$mn)
28
Belize
28
Industry Risk Reward Ratings
29
Americas Risk/Reward Ratings
29
Central America Risk/Reward Ratings
33
Industry Trends And Developments
34
Regional Developments
34
Guatemala
36
Costa Rica
37
El Salvador
41
Panama
43
Honduras
43
Nicaragua
45
Belize
46
Epidemiology
47
Clinical Trials
48
Regulatory Development
51
Regulatory Regime
51
Intellectual Property Regime
51
Costa Rica
52
El Salvador
53
Honduras
53
Nicaragua
54
Panama
54
Guatemala
54
Competitive Landscape
55
Company Profile
56
Ancalmo Internacional
56
Donovan Werke
58
Glossary
60
Methodology
62
Pharmaceutical Expenditure Forecast Model
62
Healthcare Expenditure Forecast Model
62
Notes On Methodology
63
Risk/Reward Ratings Methodology
64
Ratings Overview
65
Table: Pharmaceutical Risk/Reward Ratings Indicators
65
Indicator Weightings
66

The Central America Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Central America Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Panamanian, Guatemalan, Nicaraguan, Salvadoran, Costa Rican, Belizean, Honduran pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Panama, Guatemala, Nicaragua, El Salvador, Costa Rica, Belize, Honduras to test other views - a key input for successful budgeting and strategic business planning in the Panamanian, Guatemalan, Nicaraguan, Salvadoran, Costa Rican, Belizean, Honduran pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Panamanian, Guatemalan, Nicaraguan, Salvadoran, Costa Rican, Belizean, Honduran pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Panama, Guatemala, Nicaragua, El Salvador, Costa Rica, Belize, Honduras.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc